Cite
HARVARD Citation
Huang, Q. et al. (2020). Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia. Current medical research and opinion. pp. 2009-2018. [Online].